The development of 2-phenylbenzoxazoles as inhibitors of cholesteryl ester transfer protein (CETP) is described. Efforts focused on finding suitable replacements for the central piperidine with the aim of reducing hERG binding: a main liability of our benchmark benzoxazole (1a). Replacement of the piperidine with a cyclohexyl group successfully attenuated hERG binding, but was accompanied by reduced in vivo efficacy. The approach of substituting a piperidine moiety with an oxazolidinone also attenuated hERG binding. Further refinement of this latter scaffold via SAR at the pyridine terminus and methyl branching on the oxazolidinone led to compounds 7e and 7f, which raised HDLc by 33 and 27mg/dl, respectively, in our transgenic mouse PD model and without the hERG liability of previous series.
Authors: Ramzi F Sweis, Julianne A Hunt, Peter J Sinclair, Ying Chen, Suzanne S Eveland, Qiu Guo, Sheryl A Hyland, Denise P Milot, Anne-Marie Cumiskey, Melanie Latham, Raymond Rosa, Larry Peterson, Carl P Sparrow, Matt S Anderson